Bimiralisib

N/A

Report date: 2024/03/21 20:00:29
NME

Base Information

Drug NameBimiralisib
Drug Alias NamePQR-309
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitorsSerine/threonine-protein kinase mTOR inhibitors
TargetsPI3-kinase class ISerine/threonine-protein kinase mTOR
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursCentral Nervous System Lymphoma +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBosnia and HerzegovinaUnited StatesSerbia +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPiqur Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesTORQUR Inc
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterPiqur Therapeutics Ag
Active IndicationsKeratosis, Actinic
Inactive IndicationsMetastatic breast cancerSolid tumoursCentral Nervous System Lymphoma +[8] 

Other Information

ATC CodeN/A
Related LinksN/A